Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level

Shutterstock photo

Medtronic plc MDT and Mazor Robotics Ltd recently announced an amendment to their existing partnership,which was initially signed in May 2016 to distribute a range of Mazor products. Per the modification, the companies have entered the next phase of the agreement earlier than expected.

Mazor Robotics is an Israel-based medical device company in the field of robotic surgical guidance systems.Meanwhile, Medtronic will assume the rights to exclusive worldwide distribution of the Mazor X system (Mazor Robotic's spine surgery system) and will make $40-million third tranche investment in Mazor Robotics.

The early payment came on the back of the achievement of certain pre-agreed sales and marketing targets in advance. The growing demand for the Mazor X system also acted in favor.

Following the third installment, Medtronic's total investment in Mazor Robotics will rise to $71.9 million. The partnership will help the companies get a platform to explore the development of products for the spine market.

Medtronic is making consistent efforts to expand its spine business under the Restorative Therapies Group (RTG). In the last reported first quarter of fiscal 2018, RTG reported a 2% year-over-year revenue increase at constant exchange rate, while the Spine business witnessed low single-digit growth. Also, within RTG, the company has announced plans to launch the Solera Voyager 5.5/6.0 fixation system.

According to a report by Mordor Intelligence, the global market for Spinal Surgery Devices is estimated to reach a worth of $16.6 billion by 2021 at a CAGR of 5% from 2016 to 2021. Taking the bountiful opportunities in this niche space into consideration, we believe the company's latest development is strategic.

Over the last three months, Medtronic has underperformed the broader industry . As per the last share price movement, the stock lost 6.9%, as compared to the 0.3% gain of the broader industry over this period.

Zacks Rank & Key Picks

Medtronic carries a Zacks Rank #4 (Sell). A few better-ranked medical stocks are Edwards Lifesciences Corporation EW , Lantheus Holdings, Inc. LNTH and IDEXX Laboratories, Inc. IDXX . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You cansee the complete list of today's Zacks #1 Rank stocks here.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 25.9% over the last six months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 25.8% over the last six months.

IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 5.4% over the last six months.

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Medtronic PLC (MDT): Free Stock Analysis Report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More